Pedro Morales, MD
Adult Medicine · St Petersburg, FLNPI 1023128865
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Novo Nordisk at 25.6% of the total.
Across 168 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$900
- AbbVie$744
- AstraZeneca$563
- Amgen$245
- Lilly USA, LLC$137
- Amarin Pharma, Inc.$113
- plus $811 from 20 others
What the payments were for
- Food & beverage$3,512100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $900 |
| AbbVie | 36 | $744 |
| AstraZeneca | 25 | $563 |
| Amgen | 11 | $245 |
| Lilly USA, LLC | 6 | $137 |
| Amarin Pharma, Inc. | 7 | $113 |
| Dexcom, Inc. | 5 | $109 |
| Boehringer Ingelheim | 4 | $98 |
| GSK | 4 | $78 |
| United Therapeutics Corporation | 1 | $77 |
| Shield Therapeutics Inc | 3 | $65 |
| Exact Sciences | 3 | $59 |
| Merck | 4 | $50 |
| Abbott | 2 | $49 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| Lucid Diagnostics Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Inari Medical, Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,512 in reported general payments places this provider in the 85th percentile of 195 adult medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $37,947 |
| FarxigaDapagliflozin Propanediol | 29 | $27,616 |
| EliquisApixaban | 17 | $24,758 |
| JanuviaSitagliptin Phosphate | 28 | $23,578 |
| VraylarCariprazine Hcl | 13 | $17,600 |
| JardianceEmpagliflozin | 12 | $10,291 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,430 |
| Rosuvastatin Calcium | 174 | $3,314 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $3,145 |
| Atorvastatin Calcium | 189 | $1,982 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,973 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,934 |
| SynthroidLevothyroxine Sodium | 16 | $1,449 |
| Losartan Potassium | 113 | $1,120 |
| Amlodipine Besylate | 137 | $966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $900 | $37,94731 claims |
| AstraZenecaFarxiga, Symbicort | $563 | $30,76145 claims |
| PfizerEliquis | $14 | $24,75817 claims |
| MerckJanuvia | $50 | $23,57828 claims |
| AbbVieVraylar, Synthroid | $744 | $19,04929 claims |
| Boehringer IngelheimJardiance | $98 | $10,29112 claims |
| GSKTrelegy Ellipta | $78 | $7,43012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 195 adult medicine providers in Florida.
Other adult medicine in St Petersburg
- Steven SantiagoMiami$290K
- Tammy DsouzaKissimmee$191K
- Eric SchertzerPlantation$26K
- Ricardo SerranoMerritt Island$20K
- Marlene JarinMiami Beach$18K
- Myra ReedPanama City Beach$16K
- Joshua RycusCoral Springs$13K
- Frederick WeigandDeltona$9K
- Hernando ChongMiami$9K
- Neri FranzonFt Lauderdale$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.